Christian Dopfer
Overview
Explore the profile of Christian Dopfer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ehlers G, Todtmann A, Holsten L, Willers M, Heckmann J, Schoning J, et al.
Nat Commun
. 2025 Mar;
16(1):2239.
PMID: 40050264
Neonates primarily rely on innate immune defense, yet their inflammatory responses are usually restricted compared to adults. This is controversially interpreted as a sign of immaturity or essential programming, increasing...
2.
Schroder D, Schmachtenberg T, Heinemann S, Mullenmeister C, Roder S, El-Sayed I, et al.
J Prim Care Community Health
. 2024 May;
15:21501319241255592.
PMID: 38805375
Objectives: This study aims to investigate the impact of gender and parental tasks on social participation, health-related quality of life (hrQoL), and mental health in persons with long COVID. Methods:...
3.
Schutz K, Pallenberg S, Kontsendorn J, DeLuca D, Sukdolak C, Minso R, et al.
Front Pharmacol
. 2023 Jul;
14:1171544.
PMID: 37469865
Triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) was introduced in August 2020 in Germany for people with CF (pwCF) ≥12 years (yrs.) of age and...
4.
Pallenberg S, Held I, Dopfer C, Minso R, Nietert M, Hansen G, et al.
Front Pharmacol
. 2023 Apr;
14:1153656.
PMID: 37050906
Evidence for the efficiency of highly-effective triple-CFTR-modulatory therapy with elexacaftor/tezacaftor/ivacaftor (ETI), either demonstrated in clinical trials or by testing, is lacking for about 10% of people with cystic fibrosis (pwCF)...
5.
Schutz K, Grewendorf S, Kontsendorn J, Fuge J, Happle C, Rudolf I, et al.
Klin Padiatr
. 2023 Feb;
235(2):75-83.
PMID: 36758577
Background: Pseudomonas aeruginosa (Pa) continues to affect disease progression in cystic fibrosis (CF). However, the best eradication regimen remains unclear. This work compares three different antibiotic eradication regimens in pediatric...
6.
Habener A, Grychtol R, Gaedcke S, DeLuca D, Dittrich A, Happle C, et al.
Eur Respir J
. 2022 May;
60(5).
PMID: 35595320
Background: Comprehensive studies investigated the role of T-cells in asthma which led to personalised treatment options targeting severe eosinophilic asthma. However, little is known about the contribution of B-cells to...
7.
Maison N, Omony J, Illi S, Thiele D, Skevaki C, Dittrich A, et al.
Eur Respir J
. 2022 Feb;
60(3).
PMID: 35210326
Rationale: In adults, personalised asthma treatment targets patients with type 2 (T2)-high and eosinophilic asthma phenotypes. It is unclear whether such classification is achievable in children. Objectives: To define T2-high...
8.
de Oliveira Mekonnen A, Schwerk N, Schutz K, Schramm L, Dreissig A, Grewendorf S, et al.
Klin Padiatr
. 2022 Feb;
234(5):317-319.
PMID: 35139546
Pulmonary Alveolar Microlithiasis (PAM) is a rare hereditary lung disease caused by biallelic pathogenic variants (pV) in the solute family 34 member 2 gene ( Izumi et al., Am J...
9.
Schutz K, Kontsendorn J, Janzen N, Fuge J, Grewendorf S, Klemann C, et al.
Klin Padiatr
. 2022 Jan;
234(5):284-292.
PMID: 35098497
Background: Newborn screening (NBS) has been shown to improve cystic fibrosis (CF) disease course and has been widely implemented worldwide. This monocentric study compared children diagnosed by NBS vs. a...
10.
Zollkau J, Ankert J, Pletz M, Mishra S, Seliger G, Lobmaier S, et al.
Pathogens
. 2022 Jan;
11(1).
PMID: 35056006
Background: Infections, as well as adverse birth outcomes, may be more frequent in migrant women. Schistosomiasis, echinococcosis, and hepatitis E virus (HEV) seropositivity are associated with the adverse pregnancy outcomes...